Biodesix Inc. (BDSX)
Biodesix Statistics
Share Statistics
Biodesix has 146.44M shares outstanding. The number of shares has increased by 27.28% in one year.
| Shares Outstanding | 146.44M |
| Shares Change (YoY) | 27.28% |
| Shares Change (QoQ) | 0.35% |
| Owned by Institutions (%) | 40.09% |
| Shares Floating | 74.14M |
| Failed to Deliver (FTD) Shares | 1K |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 1.02M, so 0.7% of the outstanding shares have been sold short.
| Short Interest | 1.02M |
| Short % of Shares Out | 0.7% |
| Short % of Float | 1.12% |
| Short Ratio (days to cover) | 2.57 |
Valuation Ratios
The PE ratio is -4.62 and the forward PE ratio is -3.82. Biodesix's PEG ratio is 0.1.
| PE Ratio | -4.62 |
| Forward PE | -3.82 |
| PS Ratio | 2.78 |
| Forward PS | 0.4 |
| PB Ratio | 9.5 |
| P/FCF Ratio | -3.82 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Biodesix.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 2.97.
| Current Ratio | 2.76 |
| Quick Ratio | 2.76 |
| Debt / Equity | 2.97 |
| Debt / EBITDA | -1.8 |
| Debt / FCF | -1.19 |
| Interest Coverage | -4.18 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $261.26K |
| Profits Per Employee | $-157.26K |
| Employee Count | 273 |
| Asset Turnover | 0.73 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -59.54% in the last 52 weeks. The beta is 1.16, so Biodesix's price volatility has been higher than the market average.
| Beta | 1.16 |
| 52-Week Price Change | -59.54% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 40.24 |
| Average Volume (20 Days) | 434.28K |
Income Statement
In the last 12 months, Biodesix had revenue of 71.32M and earned -42.93M in profits. Earnings per share was -0.33.
| Revenue | 71.32M |
| Gross Profit | 71.32M |
| Operating Income | -34.5M |
| Net Income | -42.93M |
| EBITDA | -34.5M |
| EBIT | -34.67M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 26.25M in cash and 61.98M in debt, giving a net cash position of -35.73M.
| Cash & Cash Equivalents | 26.25M |
| Total Debt | 61.98M |
| Net Cash | -35.73M |
| Retained Earnings | -462.5M |
| Total Assets | 97.24M |
| Working Capital | 25.17M |
Cash Flow
In the last 12 months, operating cash flow was -48.65M and capital expenditures -3.23M, giving a free cash flow of -51.88M.
| Operating Cash Flow | -48.65M |
| Capital Expenditures | -3.23M |
| Free Cash Flow | -51.88M |
| FCF Per Share | -0.4 |
Margins
Gross margin is 100%, with operating and profit margins of -48.37% and -60.19%.
| Gross Margin | 100% |
| Operating Margin | -48.37% |
| Pretax Margin | -60.19% |
| Profit Margin | -60.19% |
| EBITDA Margin | -48.37% |
| EBIT Margin | -48.37% |
| FCF Margin | -72.74% |
Dividends & Yields
BDSX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BDSX is $2.9, which is 447.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.9 |
| Price Target Difference | 447.2% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -6.15 |
| Piotroski F-Score | 3 |